Relationships between metastasis-associated protein (MTA) 1 and lymphatic metastasis in tonsil cancer.
We evaluated immunohistochemically the expression profiles of metastasis-associated protein (MTA) 1 and their associations with lymph node metastasis in tonsil cancer. Immunohistochemical analysis of 43 tonsillar neoplasm tissues was performed using antibodies raised to MTA1. Depth of tumor invasion, lymph node metastasis, and clinical outcomes were assessed. Clinical N0 patients were divided into two groups: N0a, negative for MTA1; N0b, positive for MTA1. Occult node metastasis was reevaluated according to the revised clinical N staging system taking account of MTA1 expression. The expression rate of MTA1 was 41.9%. There was a significant correlation between the expression of MTA1 and lymph node metastasis (P = 0.034*). MTA1 had a sensitivity of 53.3% and a specificity of 84.6% for identification of cervical metastases. When cN0b patients were considered to be N+, the recalculated rate of occult metastasis fell from 50% to 7.6% (the false-positive rate remained unchanged). MTA1 was found to be a useful molecular marker to predict lymphatic metastasis in tonsil cancer.
Department of Otolaryngology-Head and Neck Surgery, The Catholic University of Korea, 505 Banpodong Seochogu Seoul St. Mary's Hospital, Seoul, 137-040, Korea.
Jun-Ook
JO
Park
Chan-Kwon
CK
Jung
Dong-Il
DI
Sun
Young-Hoon
YH
Joo
Min-Sik
MS
Kim
D014408:Biomarkers, Tumor / Q000378:metabolism*; D001707:Biopsy, Needle; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006655:Histone Deacetylases / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008197:Lymph Node Excision / Q000379:methods; D008207:Lymphatic Metastasis; D008297:Male; D037981:Neck Dissection / Q000379:methods; D009367:Neoplasm Staging; D011379:Prognosis; D012097:Repressor Proteins / Q000378:metabolism*; D012189:Retrospective Studies; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D014067:Tonsillar Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D014068:Tonsillectomy / Q000379:methods; D015534:Trans-Activators
D014408:Biomarkers, Tumor; C089320:MTA1 protein, human; D012097:Repressor Proteins; D015534:Trans-Activators; D006655:Histone Deacetylases
Oncol Rep. 2007 Nov;18(5):1311-4
17914590
Gan To Kagaku Ryoho. 1994 Nov;21(15):2541-8
7526801
Clin Exp Metastasis. 2005;22(8):653-62
16703414
J Natl Cancer Inst. 1998 Dec 16;90(24):1901-3
9862628
Cancer Res. 2004 Feb 1;64(3):825-9
14871807
Hepatology. 2008 Mar;47(3):929-36
18306220
Oncol Rep. 2006 Oct;16(4):929-35
16969516
Zhonghua Er Bi Yan Hou Ke Za Zhi. 2003 Jun;38(3):213-6
14515783
Mol Cell. 1998 Dec;2(6):851-61
9885572
DNA Cell Biol. 1994 Oct;13(10):1021-8
7945934
Cancer Sci. 2006 May;97(5):374-9
16630134
Int J Oral Maxillofac Surg. 2008 Nov;37(11):1039-46
18640824
Cancer Res. 2006 Dec 1;66(23):11110-4
17145852
Int J Cancer. 1997 Aug 22;74(4):459-63
9291440